Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 423)
Posted On: 04/13/2018 6:01:25 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Patented Drug Delivery Portfolio with New Breakthroughs
- Novel drug delivery system scientifically proven to increase absorption, bioavailability and efficacy
- New U.S. patents awarded, strengthening company’s IP portfolio
- Wide variety of patent families with ranging applications
Building off DehydraTECH™, its patented lipophilic drug delivery platform, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has received another new Notice of Allowance from the United States Patent and Trademark Office that protects the company’s processes for making specific compositions of matter for enhanced cannabinoid delivery (http://nnw.fm/ww5QV). This latest announcement comes on the heels of Lexaria’s March 22, 2018, press release that announced its receipt of a Notice of Allowance for the compositions of matter that protect the specific combination of substances which enable improved taste and bioabsorption properties of its DehydraTECH™ technology for the delivery of cannabinoids (http://nnw.fm/Llx8u). With over 35 patents pending worldwide, it’s expected that these recent notices will lead to Lexaria’s third and fourth granted United States patents.
These patents will protect processes for making specific compositions of matter and methods of manufacture and use for Lexaria’s cost-effective lipophilic delivery technology, DehydraTECH™. Lexaria’s innovative technology has been laboratory and market proven to enhance the performance of beneficial compounds in ingestible products. The gastrointestinal tract doesn’t absorb cannabinoids easily, causing wide deviation in onset times and effectiveness. Lexaria’s lipophilic enhancement technology increases the bio-absorption of cannabinoids by between five and 10 times that of traditional edibles. The onset times are also reduced by about 75 percent due to rapid bio-absorption and suspected liver bypass. Already scientifically proven to enhance absorption of orally ingested cannabinoids, Lexaria’s novel drug delivery platform is applicable across a wide range of different vitamins, drug types and cannabinoids, dramatically impacting bio-absorption and bioavailability, as well as taste, smell and speed of action.
Lexaria’s DehydraTECH™ intellectual property portfolio now consists of a wide variety of patent families covering a broad range of lipophilic active substances in foods, beverages and nutritional supplements, as well as in topical preparations and pharmaceutical dosage forms.
Lexaria’s novel drug delivery technology is a potential game changer for the delivery methodologies of many commonly used active pharmaceutical substances. With proven efficacy in the delivery of all cannabinoids, Lexaria’s complementary technology could prove immensely important for cannabinoid biopharmaceutical companies, as well as an array of other pharma and food companies. The technology provides an additional layer of effectiveness designed to harmonize with the intellectual properties of manufacturers, and it can be used with both patented and generic pharmaceutical substances.
Already out-licensing its technology, Lexaria’s is well on its way to fully implementing its long-term strategy of partnering with leading pharmaceutical, biopharma, nutraceutical, vitamin and food companies to make payload delivery predictable, safer and more effective. With the broad applications of Lexaria’s disruptive drug delivery platform and the ever-increasing portfolio of valuable patents, Lexaria appears to have the potential to dramatically alter the delivery mechanisms of a wide range orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. The ramifications of such a transformation in drug delivery could bode exceptionally well for current and future shareholders.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Novel drug delivery system scientifically proven to increase absorption, bioavailability and efficacy
- New U.S. patents awarded, strengthening company’s IP portfolio
- Wide variety of patent families with ranging applications
Building off DehydraTECH™, its patented lipophilic drug delivery platform, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has received another new Notice of Allowance from the United States Patent and Trademark Office that protects the company’s processes for making specific compositions of matter for enhanced cannabinoid delivery (http://nnw.fm/ww5QV). This latest announcement comes on the heels of Lexaria’s March 22, 2018, press release that announced its receipt of a Notice of Allowance for the compositions of matter that protect the specific combination of substances which enable improved taste and bioabsorption properties of its DehydraTECH™ technology for the delivery of cannabinoids (http://nnw.fm/Llx8u). With over 35 patents pending worldwide, it’s expected that these recent notices will lead to Lexaria’s third and fourth granted United States patents.
These patents will protect processes for making specific compositions of matter and methods of manufacture and use for Lexaria’s cost-effective lipophilic delivery technology, DehydraTECH™. Lexaria’s innovative technology has been laboratory and market proven to enhance the performance of beneficial compounds in ingestible products. The gastrointestinal tract doesn’t absorb cannabinoids easily, causing wide deviation in onset times and effectiveness. Lexaria’s lipophilic enhancement technology increases the bio-absorption of cannabinoids by between five and 10 times that of traditional edibles. The onset times are also reduced by about 75 percent due to rapid bio-absorption and suspected liver bypass. Already scientifically proven to enhance absorption of orally ingested cannabinoids, Lexaria’s novel drug delivery platform is applicable across a wide range of different vitamins, drug types and cannabinoids, dramatically impacting bio-absorption and bioavailability, as well as taste, smell and speed of action.
Lexaria’s DehydraTECH™ intellectual property portfolio now consists of a wide variety of patent families covering a broad range of lipophilic active substances in foods, beverages and nutritional supplements, as well as in topical preparations and pharmaceutical dosage forms.
Lexaria’s novel drug delivery technology is a potential game changer for the delivery methodologies of many commonly used active pharmaceutical substances. With proven efficacy in the delivery of all cannabinoids, Lexaria’s complementary technology could prove immensely important for cannabinoid biopharmaceutical companies, as well as an array of other pharma and food companies. The technology provides an additional layer of effectiveness designed to harmonize with the intellectual properties of manufacturers, and it can be used with both patented and generic pharmaceutical substances.
Already out-licensing its technology, Lexaria’s is well on its way to fully implementing its long-term strategy of partnering with leading pharmaceutical, biopharma, nutraceutical, vitamin and food companies to make payload delivery predictable, safer and more effective. With the broad applications of Lexaria’s disruptive drug delivery platform and the ever-increasing portfolio of valuable patents, Lexaria appears to have the potential to dramatically alter the delivery mechanisms of a wide range orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. The ramifications of such a transformation in drug delivery could bode exceptionally well for current and future shareholders.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)